Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Review, H1 2015

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Review, H1 2015', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 8

Therapeutics Development 9

Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Overview 9

Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Comparative Analysis 10

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Therapeutics under Development by Companies 11

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Therapeutics under Investigation by Universities/Institutes 12

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Products under Development by Companies 16

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Products under Investigation by Universities/Institutes 18

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Companies Involved in Therapeutics Development 19

Altor BioScience Corporation 19

Bavarian Nordic A/S 20

Cold Genesys, Inc. 21

Heat Biologics, Inc. 22

Marina Biotech, Inc. 23

Oncogenex Pharmaceuticals, Inc. 24

Spectrum Pharmaceuticals, Inc. 25

TARIS BioMedical, Inc. 26

Telesta Therapeutics Inc. 27

Vakzine Projekt Management GmbH 28

Viralytics Ltd. 29

Viventia Biotechnologies Inc. 30

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

ALT-801-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ALT-803-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

apatorsen-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

apaziquone-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

APL-1202-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Biologic for Superficial Bladder Cancer-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

CG-0070-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

CV-301-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

CVA-21-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

DAB-389EGF-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Drug for NMIBC-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

MDR-09521-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

oportuzumab monatox-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

rAd-IFN-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

sirolimus albumin-bound-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

TD-210-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Urocidin-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

vesigenurtucel-L-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

VPM-1002-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Recent Pipeline Updates 74

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Dormant Projects 91

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Discontinued Products 92

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Product Development Milestones 93

Featured News & Press Releases 93

Mar 09, 2015: Heat Biologics Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer 93

Feb 26, 2015: Heat Biologics Provides Update at Key Opinion Leader Event 93

Jan 26, 2015: Heat Biologics Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015 94

Dec 01, 2014: Telesta Therapeutics Announces Key Clinical & Corporate Updates 95

Nov 05, 2014: Bioniche Life Sciences provides Orphan Drug Designation Update 95

Aug 04, 2014: Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies 96

Jul 18, 2014: Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States 97

Nov 05, 2012: Bioniche Life Sciences Discontinues Phase III Clinical Trial Of Urocidin 97

Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials 98

Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2015 9

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Products under Investigation by Universities/Institutes, H1 2015 18

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Altor BioScience Corporation, H1 2015 19

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Bavarian Nordic A/S, H1 2015 20

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Cold Genesys, Inc., H1 2015 21

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Heat Biologics, Inc., H1 2015 22

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Marina Biotech, Inc., H1 2015 23

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 24

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 25

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by TARIS BioMedical, Inc., H1 2015 26

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Telesta Therapeutics Inc., H1 2015 27

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Vakzine Projekt Management GmbH, H1 2015 28

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Viralytics Ltd., H1 2015 29

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline by Viventia Biotechnologies Inc., H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics-Recent Pipeline Updates, H1 2015 74

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Dormant Projects, H1 2015 91

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Discontinued Products, H1 2015 92

List of Figures

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2015 9

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corporation

Bavarian Nordic A/S

Cold Genesys, Inc.

Heat Biologics, Inc.

Marina Biotech, Inc.

Oncogenex Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

TARIS BioMedical, Inc.

Telesta Therapeutics Inc.

Vakzine Projekt Management GmbH

Viralytics Ltd.

Viventia Biotechnologies Inc.

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutic Products under Development, Key Players in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Overview, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com